Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
Background Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai, BA Jonas… - The Lancet …, 2018 - pure.johnshopkins.edu
Background: Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai… - The Lancet …, 2018 - einstein.elsevierpure.com
Background: Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei… - The Lancet …, 2018 - Elsevier
Background Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai, BA Jonas… - The Lancet …, 2018 - research.monash.edu
Background: Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai, BA Jonas… - The Lancet …, 2018 - europepmc.org
Background Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
[引用][C] Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non …
CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei… - The Lancet …, 2018 - cir.nii.ac.jp
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients
with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b …
with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai… - The lancet …, 2018 - mdanderson.elsevierpure.com
Background: Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised …
CD DiNardo, KW Pratz, A Letai… - The Lancet …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
[PDF][PDF] Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non …
CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei… - 2018 - thd.org.tr
Background Elderly patients (aged≥ 65 years) with acute myeloid leukaemia have poor
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …
outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating …